NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its quarterly earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.61) by $0.01. The biopharmaceutical company earned $35.59 million during the quarter, compared to analyst estimates of $32.31 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.36% and a negative net margin of 388.30%. View Ultragenyx Pharmaceutical's Earnings History.

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million.

10 brokerages have issued 12 month target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $70.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $78.33 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

News headlines about RARE stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 3.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Ultragenyx Pharmaceutical.

Some companies that are related to Ultragenyx Pharmaceutical include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Gilead Sciences (GILD), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), GALAPAGOS NV/S (GLPG), Netflix (NFLX), Sangamo Therapeutics (SGMO), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Vertex Pharmaceuticals (VRTX).

Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.01%), Capital International Investors (10.46%), Capital World Investors (5.60%), State Street Corp (3.81%), FMR LLC (3.16%) and Alliancebernstein L.P. (2.68%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Capital Bank & Trust Co, Rafferty Asset Management LLC, Capital International Inc. CA, Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC and Laurion Capital Management LP. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

RARE stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Franklin Resources Inc., Alliancebernstein L.P., EcoR1 Capital LLC, First Trust Advisors LP, Pinnacle Associates Ltd., State Street Corp and Barclays PLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $59.39.

Ultragenyx Pharmaceutical has a market capitalization of $3.44 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]